Natus Medical Inc. (BABY) Earns Buy Rating from Analysts at Benchmark Co.
Stock analysts at Benchmark Co. assumed coverage on shares of Natus Medical Inc. (NASDAQ:BABY) in a report issued on Tuesday. The firm set a “buy” rating on the stock.
A number of other equities research analysts have also issued reports on the company. Zacks Investment Research lowered Natus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, September 28th. Raymond James Financial Inc. upgraded Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price objective for the company in a research note on Tuesday, September 13th.
Shares of Natus Medical (NASDAQ:BABY) opened at 39.91 on Tuesday. Natus Medical has a 52 week low of $29.54 and a 52 week high of $51.05. The firm has a 50-day moving average price of $40.44 and a 200-day moving average price of $36.82. The stock has a market cap of $1.29 billion, a PE ratio of 34.41 and a beta of 0.78.
Natus Medical (NASDAQ:BABY) last released its quarterly earnings data on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, topping analysts’ consensus estimates of $0.36 by $0.03. The company had revenue of $96 million for the quarter, compared to the consensus estimate of $92.71 million. Natus Medical had a return on equity of 13.82% and a net margin of 10.20%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $0.34 EPS. On average, analysts forecast that Natus Medical will post $1.58 earnings per share for the current fiscal year.
In other Natus Medical news, insider James B. Hawkins acquired 10,000 shares of the stock in a transaction on Wednesday, September 28th. The stock was purchased at an average price of $38.48 per share, for a total transaction of $384,800.00. Following the purchase, the insider now directly owns 459,725 shares in the company, valued at $17,690,218. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.80% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of BABY. BlackRock Group LTD raised its position in shares of Natus Medical by 5.9% in the first quarter. BlackRock Group LTD now owns 50,792 shares of the company’s stock valued at $1,952,000 after buying an additional 2,839 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Natus Medical by 227.5% in the first quarter. JPMorgan Chase & Co. now owns 96,350 shares of the company’s stock valued at $3,703,000 after buying an additional 66,933 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its position in shares of Natus Medical by 13.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 953,413 shares of the company’s stock valued at $36,640,000 after buying an additional 112,582 shares during the last quarter. Invictus RG purchased a new position in shares of Natus Medical during the first quarter valued at approximately $148,000. Finally, BNP Paribas Arbitrage SA raised its position in shares of Natus Medical by 120.8% in the second quarter. BNP Paribas Arbitrage SA now owns 10,316 shares of the company’s stock valued at $390,000 after buying an additional 5,643 shares during the last quarter. Institutional investors own 87.92% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related stocks with our FREE daily email newsletter.